The sustained cardiopulmonary benefits strengthen the clinical and regulatory case for z-rostudirsen, potentially de-risking the path to FDA accelerated approval. Traders should monitor for upcoming interactions with the FDA and potential BLA submission timelines.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 9 $17.69entry
- T+1 · 8mo ago +11.81%α +12.00% · $19.78
- T+5 · 8mo ago +2.49%α +3.84% · $18.13
- T+20 · 7mo ago +2.66%α +5.46% · $18.16
- T+60 · 6mo ago −2.54%α −14.53% · $17.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER trial showing sustained functional improvements in heart and lung function for DMD patients treated with z-rostudirsen, a therapy targeting exon 51 skipping. The results, presented at the 2026 MDA Conference, suggest potential clinical benefits beyond muscle function, including cardiopulmonary improvements compared to natural history decline.
Key Facts
- 24-month data from the DELIVER trial show improvement in lung function (FVC%p), circumferential strain, and left ventricular ejection fraction vs. expected decline in natural history.
- Z-rostudirsen demonstrated a favorable safety profile with mostly mild or moderate TEAEs; no related serious adverse events in the registrational cohort.
- Therapy has FDA Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for DMD amenable to exon 51 skipping.
- Most participants at 24 months were on lower doses than the registrational 20 mg/kg, suggesting potential for even greater efficacy at full dose.
- Data presented at a late-breaking session at the 2026 MDA Clinical & Scientific Conference.
Financial Impact
Potential path to accelerated approval; increases likelihood of future revenue and partnership interest
Risk Factors
- Long-term efficacy may not reflect full potential, as most patients were not continuously on the 20 mg/kg registrational dose.
- Forward-looking statements carry inherent risk; final trial results or regulatory decisions may differ.
- No Phase 3 data yet; approval remains contingent on confirmatory trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251476 |
Track record
54 reports on DYN
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers